JP2007518767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007518767A5 JP2007518767A5 JP2006550041A JP2006550041A JP2007518767A5 JP 2007518767 A5 JP2007518767 A5 JP 2007518767A5 JP 2006550041 A JP2006550041 A JP 2006550041A JP 2006550041 A JP2006550041 A JP 2006550041A JP 2007518767 A5 JP2007518767 A5 JP 2007518767A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- -1 cyano, hydroxy Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 claims 1
- 108010085273 Adenosine A2B receptor Proteins 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 description 12
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0401336.3A GB0401336D0 (en) | 2004-01-21 | 2004-01-21 | Organic compounds |
| PCT/EP2005/000542 WO2005070926A1 (en) | 2004-01-21 | 2005-01-20 | Thiazole derivatives as a2b antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007518767A JP2007518767A (ja) | 2007-07-12 |
| JP2007518767A5 true JP2007518767A5 (enExample) | 2008-03-21 |
Family
ID=31971241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550041A Pending JP2007518767A (ja) | 2004-01-21 | 2005-01-20 | Ａ２ｂアンタゴニストとしてのチアゾール誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090233938A1 (enExample) |
| EP (1) | EP1709036B1 (enExample) |
| JP (1) | JP2007518767A (enExample) |
| KR (1) | KR20060129276A (enExample) |
| CN (1) | CN1910178B (enExample) |
| AT (1) | ATE388147T1 (enExample) |
| AU (1) | AU2005206290B2 (enExample) |
| BR (1) | BRPI0506927A (enExample) |
| CA (1) | CA2553010A1 (enExample) |
| DE (1) | DE602005005161T2 (enExample) |
| ES (1) | ES2300985T3 (enExample) |
| GB (1) | GB0401336D0 (enExample) |
| PL (1) | PL1709036T3 (enExample) |
| PT (1) | PT1709036E (enExample) |
| RU (1) | RU2374242C2 (enExample) |
| WO (1) | WO2005070926A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| NZ566036A (en) * | 2005-09-13 | 2010-06-25 | Janssen Pharmaceutica Nv | 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| WO2007109547A2 (en) | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| JP5026511B2 (ja) | 2006-05-18 | 2012-09-12 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシンａ２ｂレセプターアンタゴニストとしてのチアゾロ−ピラミジン／ピリジン尿素誘導体 |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| ES2424023T3 (es) | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
| MY152486A (en) | 2008-03-19 | 2014-10-15 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators |
| US8779158B2 (en) | 2008-05-09 | 2014-07-15 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| CN109293652B (zh) * | 2017-07-24 | 2021-10-22 | 四川科伦博泰生物医药股份有限公司 | 一种取代的噻唑衍生物及其用途 |
| WO2019072143A1 (zh) * | 2017-10-11 | 2019-04-18 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| WO2020083957A1 (en) | 2018-10-24 | 2020-04-30 | Leadxpro Ag | Functionalized aminotriazines |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| US20250101013A1 (en) * | 2022-01-19 | 2025-03-27 | Leadxpro Ag | Functionalized aminothiazoles |
| GB2615307A (en) * | 2022-01-28 | 2023-08-09 | Adorx Therapeutics Ltd | Antagonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| WO1999064418A1 (en) * | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
| JP2000281685A (ja) * | 1999-01-28 | 2000-10-10 | Takeda Chem Ind Ltd | チアゾロピリミジン化合物、その製造法および用途 |
| WO2001030778A1 (en) * | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| JP2002302445A (ja) * | 2001-02-02 | 2002-10-18 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| GB0123589D0 (en) * | 2001-10-01 | 2001-11-21 | Syngenta Participations Ag | Organic compounds |
| JP2005510508A (ja) * | 2001-11-08 | 2005-04-21 | 藤沢薬品工業株式会社 | アデノシンアンタゴニストとしてのチアゾールピリダジノン類 |
-
2004
- 2004-01-21 GB GBGB0401336.3A patent/GB0401336D0/en not_active Ceased
-
2005
- 2005-01-20 ES ES05706936T patent/ES2300985T3/es not_active Expired - Lifetime
- 2005-01-20 BR BRPI0506927-0A patent/BRPI0506927A/pt not_active IP Right Cessation
- 2005-01-20 CA CA002553010A patent/CA2553010A1/en not_active Abandoned
- 2005-01-20 CN CN2005800026886A patent/CN1910178B/zh not_active Expired - Fee Related
- 2005-01-20 AT AT05706936T patent/ATE388147T1/de not_active IP Right Cessation
- 2005-01-20 RU RU2006130002/04A patent/RU2374242C2/ru not_active IP Right Cessation
- 2005-01-20 US US10/585,614 patent/US20090233938A1/en not_active Abandoned
- 2005-01-20 PT PT05706936T patent/PT1709036E/pt unknown
- 2005-01-20 DE DE602005005161T patent/DE602005005161T2/de not_active Expired - Lifetime
- 2005-01-20 AU AU2005206290A patent/AU2005206290B2/en not_active Ceased
- 2005-01-20 WO PCT/EP2005/000542 patent/WO2005070926A1/en not_active Ceased
- 2005-01-20 KR KR1020067014629A patent/KR20060129276A/ko not_active Ceased
- 2005-01-20 PL PL05706936T patent/PL1709036T3/pl unknown
- 2005-01-20 EP EP05706936A patent/EP1709036B1/en not_active Expired - Lifetime
- 2005-01-20 JP JP2006550041A patent/JP2007518767A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007518767A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| AU707144B2 (en) | Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect | |
| CN115160339B (zh) | 醛糖还原酶抑制剂及其使用方法 | |
| JP2011507878A5 (enExample) | ||
| JP2007269797A5 (enExample) | ||
| JP2018507890A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2007525529A (ja) | ５−ヒドロキシインドール−３−カルボン酸エステル類誘導体およびその用途 | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2009507909A5 (enExample) | ||
| RU2007109598A (ru) | Кристаллическая форма бифенильного соединения | |
| JP2013540114A5 (enExample) | ||
| JP2004506041A5 (enExample) | ||
| JP2011507879A5 (enExample) | ||
| JP2003306481A5 (enExample) | ||
| RU2007146669A (ru) | Пролекарства антагонистов a2b рецептора аденозина | |
| CN1165522C (zh) | 缓激肽受体拮抗剂 | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| AU2014251442A1 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2007522142A5 (enExample) | ||
| JP2005526696A5 (enExample) |